The Tokyo-based biotech firm expects RV-001 to be able to alter light sensitivity for patients with limited or no vision regardless of genotype.

Inherited eye disorders such as retinitis pigmentosa (RP) leave millions grappling with progressive vision loss. At the heart of this issue is the protein rhodopsin, which, due to genetic ...

The first optogenetic 'Chimeric Rhodopsin' gene therapy tested in humans. RV-001 starting dose was generally well tolerated in this open-label trial. RV-001 a gene-agnostic approach for RP patients.

The first optogenetic "Chimeric Rhodopsin" gene therapy tested in humans. RV-001 starting dose was generally well tolerated in this open-label trial. RV-001 a gene-agnostic approach for RP patients.

In view of the oxygen-rich environment in the eye, it is particularly noteworthy that phospholipids containing docosahexaenoic acid (DHA), which are exquisitely sensitive to oxidative damage (1), are ...